Platelet transfusions

Lancet

Volumn 370, Issue 9585, 2007, Pages 427-438

  Stroncek, David F ^a   Rebulla, Paolo ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LUNG INJURY; ADVERSE OUTCOME; ALLOIMMUNIZATION; BACTERIUM CONTAMINATION; BACTERIUM DETECTION; BLOOD; BLOOD COMPONENT; BLOOD STORAGE; CLINICAL PRACTICE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNITY; OPERATION DURATION; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RECIPIENT; REVIEW; THERAPY EFFECT; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION; UNITED STATES;

EID: 34547595111     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61198-2     Document Type: Review

References (155)

1. Freireich E. Supportive care for patients with blood disorders. Br J Haematol 111 (2000) 68-77
2. Hersh E., Bodey G., Nies B., and Freireich E. Causes of death in acute leukemia: a ten-year study of 414 patients from 1954-1963. JAMA 193 (1965) 105-109
3. Sullivan M., and Wallace E. Blood collection and transfusion in the United States in 1999. Transfusion 45 (2005) 141-148
4. Maniatis A. Criteria for clinical transfusion practice. In: Rouger P., and Hossenlopp C. (Eds). Blood transfusion in Europe-the white book 2005 (2005), Elsevier SAS, Paris 205-212
5. Walters C., and Murphy Jr. W. A closed gravity technique for the preservation of whole blood in ACD solution utilizing plastic equipment. Surg Gynecol Obstet 94 (1952) 687-692
6. Buchholz D., Porten J., Menitove J., et al. Description and use of the CS-3000 blood cell separator for single-donor platelet collection. Transfusion 23 (1983) 190-196
7. Katz A., Genco P., Blumberg N., Snyder E., Camp B., and Morse E. Platelet collection and transfusion using the fenwal CS-3000 cell separator. Transfusion 21 (1981) 560-563
8. Slichter S. Efficacy of platelets collected by semi-continuous flow centrifugation (Haemonetics Model 30). Br J Haematol 38 (1978) 131-140
9. Hogman C., Berseus O., Eriksson L., and Gulliksson H. International forum: Europe. Buffy-coat-derived platelet concentrates: Swedish experience. Transfus Sci 18 (1997) 3-13
10. Pietersz R., Loos J., and Reesink H. Platelet concentrates stored in plasma for 72 hours at 22 degrees C prepared from buffycoats of citrate-phosphate-dextrose blood collected in a quadruple-bag saline-adenine-glucose-mannitol system. Vox Sang 49 (1985) 81-85
11. Murphy S., Heaton W., and Rebulla P. Platelet production in the Old World-and the New. Transfusion 36 (1996) 751-754
12. Sweeney J., Kouttab N., Holme S., Kurtis J., Cheves T., and Nelson E. Storage of platelet-rich plasma-derived platelet concentrate pools in plasma and additive solution. Transfusion 46 (2006) 835-840
13. Heddle N., Klama L., Meyer R., et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 39 (1999) 231-238
14. Dzik W., Cusack W., Sherburne B., and Kickler T. The effect of prestorage white cell reduction on the function and viability of stored platelet concentrates. Transfusion 32 (1992) 334-339
15. Fournel J., Zingsem J., Riggert J., et al. A multicenter evaluation of the routine use of a new white cell-reduction apheresis system for collection of platelets. Transfusion 37 (1997) 487-492
16. Burgstaler E., Pineda A., Potter B., and Brown R. Plateletapheresis with a next generation blood cell separator. J Clin Apher 12 (1997) 55-62
17. Keegan T., Heaton A., Holme S., Owens M., Nelson E., and Carmen R. Paired comparison of platelet concentrates prepared from platelet-rich plasma and buffy coats using a new technique with 111In and 51Cr. Transfusion 32 (1992) 113-120
18. Turner V., Hawker R., Mitchell S., and Seymour Mead A. Paired in vivo and in vitro comparison of apheresis and "recovered" platelet concentrates stored for 5 days. J Clin Apher 9 (1994) 189-194
19. Rebulla P. In vitro and in vivo properties of various types of platelets. Vox Sang 74 suppl 2 (1998) 217-222
20. Standards for Blood Banks and Transfusion Services. 23rd edn. (2004), AABB, Bethesda, Maryland
21. Guide to the preparation, use and quality assurance of blood components. 12th edn. (2006), Council of Europe Publishing, Strasbourg
22. Heaton W., Rebulla P., Pappalettera M., and Dzik W. A comparative analysis of different methods for routine blood component preparation. Transfus Med Rev 11 (1997) 116-129
23. Murphy S., Kahn R., Holme S., et al. Improved storage of platelets for transfusion in a new container. Blood 60 (1982) 194-200
24. Slichter S., and Harker L. Preparation and storage of platelet concentrates II-storage variables influencing platelet viability and function. Br J Haematol 34 (1976) 403-419
25. Hoffmeister K., Felbinger T., Falet H., et al. The clearance mechanism of chilled blood platelets. Cell 112 (2003) 87-97
26. Hoffmeister K., Josefsson E., Isaac N., Clausen H., Hartwig J., and Stossel T. Glycosylation restores survival of chilled blood platelets. Science 301 (2003) 1531-1534
27. Slichter S., Wandall H., and Hoffmeister K. In vivo studies of autologous platelets stored at room temperature (22°C), 4°C, and 4°C with galactosylation. Blood 108 (2006) 175 (abstract).
28. Heal J., Singal S., Sardisco E., and Mayer T. Bacterial proliferation in platelet concentrates. Transfusion 26 (1986) 388-390
29. van der Meer P., Gulliksson H., AuBuchon J., Prowse C., Richter E., and Wildt-Eggen J. Interruption of agitation of platelet concentrates: effects on in vitro parameters. Vox Sang 88 (2005) 227-234
30. Yomtovian R., Lazarus H., Goodnough L., Hirschler N., Morrissey A., and Jacobs M. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 33 (1993) 902-909
31. Wagner S., and Robinette D. Evaluation of swirling, pH, and glucose tests for the detection of bacterial contamination in platelet concentrates. Transfusion 36 (1996) 989-993
32. Burstain J., Brecher M., Workman K., Foster M., Faber G., and Mair D. Rapid identification of bacterially contaminated platelets using reagent strips: glucose and pH analysis as markers of bacterial metabolism. Transfusion 37 (1997) 255-258
33. Brecher M., Hogan J., Boothe G., et al. Platelet bacterial contamination and the use of a chemiluminescence-linked universal bacterial ribosomal RNA gene probe. Transfusion 34 (1994) 750-755
34. Brecher M., and Hay S. Bacterial contamination of blood components. Clin Microbiol Rev 18 (2005) 195-204
35. Wagner S., and Robinette D. Evaluation of an automated microbiologic blood culture device for detection of bacteria in platelet components. Transfusion 38 (1998) 674-679
36. Brecher M., Means N., Jere C., Heath D., Rothenberg S., and Stutzman L. Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms. Transfusion 41 (2001) 477-482
37. Ortolano G., Freundlich L., Holme S., et al. Detection of bacteria in WBC-reduced PLT concentrates using percent oxygen as a marker for bacteria growth. Transfusion 43 (2003) 1276-1285
38. Rock G., Neurath D., Toye B., et al. The use of a bacteria detection system to evaluate bacterial contamination in PLT concentrates. Transfusion 44 (2004) 337-342
39. Consensus conference. Platelet transfusion therapy. JAMA 257 (1987) 1777-1780
40. Gmur J., Burger J., Schanz U., Fehr J., and Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338 (1991) 1223-1226
41. Gil-Fernandez J., Alegre A., Fernandez-Villalta M., et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 18 (1996) 931-935
42. Heckman K., Weiner G., Davis C., Strauss R., Jones M., and Burns C. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10 000/microL versus 20 000/microL. J Clin Oncol 15 (1997) 1143-1149
43. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 337 (1997) 1870-1875
44. Wandt H., Frank M., Ehninger G., et al. Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91 (1998) 3601-3606
45. Lawrence J., Yomtovian R., Hammons T., et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma 41 (2001) 67-76
46. Guidelines for the use of platelet transfusions. Br J Haematol 122 (2003) 10-23
47. Ancliff P., and Machin S. Trigger factors for prophylactic platelet transfusion. Blood Rev 12 (1998) 234-238
48. Stanworth S., Hyde C., Heddle N., Rebulla P., Brunskill S., and Murphy M. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2 (2004) CD004269.
49. Schiffer C., Anderson K., Bennett C., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1519-1538
50. Strauss R. Pretransfusion trigger, platelet counts and dose for prophylactic platelet transfusions. Curr Opin Hematol 12 (2005) 499-502
51. Hanseler E., Fehr J., and Keller H. Estimation of the lower limits of manual and automated platelet counting. Am J Clin Pathol 105 (1996) 782-787
52. Wandt H., Schaefer-Eckart K., Frank M., Birkmann J., and Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37 (2006) 387-392
53. Schaefer-Eckart K., Wendelin K., Wilhelm M., et al. Interim analysis of a prospective randomized study comparing a therapeutic platelet transfusion strategy with the prophyactic platelet transfusion standard in patients after autologous peripheral blood stem cell transplantation (ASCT). Blood 108 (2006) 174 (abstract).
54. Hiippala S. Replacement of massive blood loss. Vox Sang 74 suppl 2 (1998) 399-407
55. Woodman R., and Harker L. Bleeding complications associated with cardiopulmonary bypass. Blood 76 (1990) 1680-1697
56. Harding S., Shakoor M., and Grindon A. Platelet support for cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 70 (1975) 350-353
57. Simon T., Akl B., and Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 37 (1984) 359-364
58. Murray N., and Roberts I. Neonatal transfusion practice. Arch Dis Child Fetal Neonatal Ed 89 (2004) 101-107
59. Roberts I., and Murray N. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 88 (2003) 359-364
60. Lind S. Thrombocytopenic purpura and platelet transfusion. Ann Intern Med 106 (1987) 478
61. Gordon L., Kwaan H., and Rossi E. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 24 (1987) 194-201
62. de la Rubia J., Plume G., Arriaga F., Carpio N., Sanz M., and Marty M. Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion 42 (2002) 1384-1385
63. Lozano M., Domingo A., Pereira A., Fontanals J., and Mazzara R. Platelet transfusion in thrombotic thrombocytopenic purpura: between Scylla and Charybdis. Transfusion 45 (2005) 1984
64. Carr J., Kruskall M., Kaye J., and Robinson S. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 80 (1986) 1051-1054
65. Stanworth S., Hyde C., Brunskill S., and Murphy M. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?. Br J Haematol 131 (2005) 588-595
66. Strauss R. Low-dose prophylactic platelet transfusions: time for further study, but too early for routine clinical practice. Transfusion 44 (2004) 1680-1682
67. Heddle N., Cook R., Sigouin C., Slichter S., Murphy M., and Rebulla P. A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion 46 (2006) 903-911
68. Tinmouth A., Tannock I., Crump M., et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 44 (2004) 1711-1719
69. Hanson S., and Slichter S. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 66 (1985) 1105-1109
70. Ackerman S., Klumpp T., Guzman G., et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 40 (2000) 1457-1462
71. Norol F., Bierling P., Roudot-Thoraval F., et al. Platelet transfusion: a dose-response study. Blood 92 (1998) 1448-1453
72. Sensebe L., Giraudeau B., Bardiaux L., et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 105 (2005) 862-864
73. Kuter D., Goodnough L., Romo J., et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98 (2001) 1339-1345
74. Goodnough L., Kuter D., McCullough J., et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 98 (2001) 1346-1351
75. Li J., Yang C., Xia Y., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241-3248
76. O'Connell B., Lee E., and Schiffer C. The value of 10-minute posttransfusion platelet counts. Transfusion 281 (1988) 66-67
77. Rebulla P. A mini-review on platelet refractoriness. Haematologica 90 (2005) 247-253
78. Bishop J., Matthews J., Yuen K., McGrath K., Wolf M., and Szer J. The definition of refractoriness to platelet transfusions. Transfus Med 2 (1992) 35-41
79. Rebulla P. Formulae for the definition of refractoriness to platelet transfusion. Transfus Med 3 (1993) 91-93
80. Schiffer C., Lee E., Ness P., and Reilly J. Clinical evaluation of platelet concentrates stored for one to five days. Blood 67 (1986) 1591-1594
81. Lee E., and Schiffer C. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 29 (1989) 384-389
82. Salama M., Raman S., Drew M., Abdel-Raheem M., and Mahmood M. Platelet function testing to assess effectiveness of platelet transfusion therapy. Transfus Apher Sci 30 (2004) 93-100
83. Cook R., Heddle N., Rebulla P., Sigouin C., and Webert K. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion 44 (2004) 1135-1142
84. Legler T., Fischer I., Dittmann J., et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 74 (1997) 185-189
85. Doughty H., Murphy M., Metcalfe P., Rohatiner A., Lister T., and Waters A. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 66 (1994) 200-205
86. Novotny V., van Doorn R., Witvliet M., Claas F., and Brand A. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 85 (1995) 1736-1741
87. Klumpp T., Herman J., Innis S., et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 17 (1996) 1035-1041
88. Bock M., Muggenthaler K., Schmidt U., and Heim M. Influence of antibiotics on posttransfusion platelet increment. Transfusion 36 (1996) 952-954
89. Bishop J., Matthews J., McGrath K., Yuen K., Wolf M., and Szer J. Factors influencing 20-hour increments after platelet transfusion. Transfusion 31 (1991) 392-396
90. Slichter S., Davis K., Enright H., et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105 (2005) 4106-4114
91. Balduini C., Salvaneschi L., Klersy C., et al. Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation. Leukemia 15 (2001) 1885-1891
92. Brittingham T. Immunologic studies on leucocytes. Vox Sang 2 (1957) 242-248
93. Howard J., and Perkins H. The natural history of alloimmunization to platelets. Transfusion 18 (1978) 496-503
94. Leucocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 337 (1997) 1861-1869
95. Laundy G., Bradley B., Rees B., Younie M., and Hows J. Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion 44 (2004) 814-825
96. Sanz C., Freire C., Alcorta I., Ordinas A., and Pereira A. Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 41 (2001) 762-765
97. Schnaidt M., Northoff H., and Wernet D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 6 (1996) 111-114
98. Dunstan R., Simpson M., and Rosse W. Erythrocyte antigens on human platelets. Absence of Rh, Duffy, Kell, Kidd, and Lutheran antigens. Transfusion 24 (1984) 243-246
99. Seftel M., Growe G., Petraszko T., et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 103 (2004) 333-339
100. Densmore T., Goodnough L., Ali S., Dynis M., and Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion 39 (1999) 103-106
101. Duquesnoy R., Filip D., Rodey G., Rimm A., and Aster R. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 2 (1977) 219-226
102. Takahashi K., Juji T., and Miyazaki H. Determination of an appropriate size of unrelated donor pool to be registered for HLA-matched platelet transfusion. Transfusion 27 (1987) 394-398
103. Bolgiano D., Larson E., and Slichter S. A model to determine required pool size for HLA-typed community donor apheresis programs. Transfusion 29 (1989) 306-310
104. Moroff G., Garratty G., Heal J., et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 32 (1992) 633-640
105. Duquesnoy R. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination; I: description of the algorithm. Hum Immunol 63 (2002) 339-352
106. Duquesnoy R., and Marrari M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination: II: Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol 63 (2002) 353-363
107. Nambiar A., Duquesnoy R., Adams S., et al. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 107 (2006) 1680-1687
108. Rebulla P., Morelati F., Revelli N., et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol 125 (2004) 83-89
109. Porretti L., Marangoni F., Rebulla P., and Sirchia G. Frozen platelet plates for platelet antibody detection and cross-match. Vox Sang 67 (1994) 52-57
110. Kurtzberg J., Friedman H., Kinney T., Chaffee S., and Falletta J. Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature. Am J Med 83 (1987) 30-33
111. Zeigler Z., Shadduck R., Rosenfeld C., et al. High-dose intravenous gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusion. Blood 70 (1987) 1433-1436
112. Yamamoto M., Ideguchi H., Nishimura J., et al. Treatment of platelet-alloimmunization with cyclosporin A in a patient with aplastic anemia. Am J Hematol 33 (1990) 220-221
113. Tilly H., Azagury M., Bastit D., Lallemand A., and Piguet H. Cyclosporin for treatment of life-threatening alloimmunization. Am J Hematol 34 (1990) 75-76
114. Bruggers C., Kurtzberg J., and Friedman H. Vincristine therapy for severe platelet alloimmunization. Am J Pediatr Hematol Oncol 13 (1991) 300-304
115. Christie D., Howe R., Lennon S., and Sauro S. Treatment of refractoriness to platelet transfusion by protein A column therapy. Transfusion 33 (1993) 234-242
116. Castro E., Muncunill J., Barea L., Gonzalez R., and Fernandez-Villalta M. Acid elution of platelets HLA-class I antigens in the treatment of a refractory patient. Br J Haematol 100 (1998) 245-246
117. Novotny V., Huizinga T., van Doorn R., Briet E., and Brand A. HLA class I-eluted platelets as an alternative to HLA-matched platelets. Transfusion 36 (1996) 438-444
118. Bowden R., Sayers M., Flournoy N., et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314 (1986) 1006-1010
119. Bowden R., Slichter S., Sayers M., et al. A comparison of filtered leucocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86 (1995) 3598-3603
120. Vamvakas E. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 19 (2005) 181-199
121. Rhame F., Root R., MacLowry J., Dadisman T., and Bennett J. Salmonella septicemia from platelet transfusions. Study of an outbreak traced to a hematogenous carrier of Salmonella cholerae-suis. Ann Intern Med 78 (1973) 633-641
122. Jafari M., Forsberg J., Gilcher R., et al. Salmonella sepsis caused by a platelet transfusion from a donor with a pet snake. N Engl J Med 347 (2002) 1075-1078
123. Haimowitz M., Hernandez L., and Herron Jr. R. A blood donor with bacteraemia. Lancet 365 (2005) 1596
124. Satake M. Infectious risks associated with the transfusion of blood components and pathogen inactivation in Japan. Int J Hematol 80 (2004) 306-310
125. Lin L., Cook D., Wiesehahn G., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37 (1997) 423-435
126. AuBuchon J., Herschel L., Roger J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 45 (2005) 1335-1341
127. Klein H. Pathogen inactivation technology: cleansing the blood supply. J Intern Med 257 (2005) 224-237
128. Pineda A., McCullough J., Benjamin R., et al. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion 46 (2006) 562-571
129. McCullough J., Vesole D., Benjamin R., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 104 (2004) 1534-1541
130. Heddle N., Klama L., Singer J., et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 331 (1994) 625-628
131. Heddle N., Blajchman M., Meyer R., et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 42 (2002) 556-566
132. Lichtiger B., and Hester J. Transfusion of Rh-incompatible blood components to cancer patients. Haematologia (Budap) 19 (1986) 81-88
133. Goldfinger D., and McGinniss M. Rh-incompatible platelet transfusions--risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 284 (1971) 942-944
134. Heim M., Bock M., Kolb H., Schleuning M., and Mempel W. Intravenous anti-D gammaglobulin for the prevention of rhesus isoimmunization caused by platelet transfusions in patients with malignant diseases. Vox Sang 62 (1992) 165-168
135. Lee D., Contreras M., Robson S., Rodeck C., and Whittle M. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. British Blood Transfusion Society and the Royal College of Obstetricians and Gynaecologists. Transfus Med 9 (1999) 93-97
136. Ford J., Cullen M., Lucey J., Tobias J., and Lister T. Fatal graft-versus-host disease following transfusion of granulocytes from normal donors. Lancet 2 (1976) 1167-1169
137. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. BCSH Blood Transfusion Task Force Transfus Med 6 (1996) 261-271
138. Leitman S., and Holland P. Irradiation of blood products. Indications and guidelines. Transfusion 25 (1985) 293-303
139. Anderson K., and Weinstein H. Transfusion-associated graft-versus-host disease. N Engl J Med 323 (1990) 315-321
140. Toy P., Popovsky M., Abraham E., et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 33 (2005) 721-726
141. Popovsky M., Abel M., and Moore S. Transfusion-related acute lung injury associated with passive transfer of antileucocyte antibodies. Am Rev Respir Dis 128 (1983) 185-189
142. Goldman M., Webert K., Arnold D., Freedman J., Hannon J., and Blajchman M. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 19 (2005) 2-31
143. Kopko P., Marshall C., MacKenzie M., Holland P., and Popovsky M. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 287 (2002) 1968-1971
144. Sachs U., Hattar K., Weissmann N., et al. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood 107 (2006) 1217-1219
145. Silliman C., and McLaughlin N. Transfusion-related acute lung injury. Blood Rev 20 (2006) 139-159
146. Kerkhoffs J., Eikenboom J., Schipperus M., et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 108 (2006) 3210-3215
147. Vassallo R. Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products. Immunohematol 20 (2004) 226-233
148. Sandler S. How I manage patients suspected of having had an IgA anaphylactic transfusion reaction. Transfusion 46 (2006) 10-13
149. McLeod B., Sassetti R., Weens J., and Vaithianathan T. Haemolytic transfusion reaction due to ABO incompatible plasma in a platelet concentrate. Scand J Haematol 28 (1982) 193-196
150. Pierce R., Reich L., and Mayer K. Hemolysis following platelet transfusions from ABO-incompatible donors. Transfusion 25 (1985) 60-62
151. Quillen K. Hypotensive transfusion reactions in patients taking angiotensin-converting-enzyme inhibitors. N Engl J Med 343 (2000) 1422-1423
152. Mascaretti L., James V., Barbara J., et al. Comparative analysis of national regulations concerning blood safety across Europe. Transfus Med 14 (2004) 105-112
153. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 45 (2005) 634-639
154. AuBuchon J., Taylor H., Holme S., and Nelson E. In vitro and in vivo evaluation of leukoreduced platelets stored for 7 days in CLX containers. Transfusion 45 (2005) 1356-1361
155. Bode A., and Read M. Lyophilized platelets: continued development. Transfus Sci 22 (2000) 99-105